Morgan Dempsey Capital Management LLC C4 Therapeutics, Inc. Transaction History
Morgan Dempsey Capital Management LLC
- $288 Million
- Q3 2024
A detailed history of Morgan Dempsey Capital Management LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Morgan Dempsey Capital Management LLC holds 1,500 shares of CCCC stock, worth $5,100. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,500Holding current value
$5,100% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
129Shares Held
63.5MCall Options Held
670KPut Options Held
54.8K-
Lynx1 Capital Management LP San Juan, PR6.88MShares$23.4 Million14.04% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.6MShares$22.5 Million3.2% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT5.68MShares$19.3 Million0.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$16.6 Million0.39% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$15.5 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $166M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...